Kiadis outlines strategy

Published: 15-Jun-2002


Dutch life sciences company Screentec, of Leiden, has changed its name to Kiadis to signify its progression to the next phase in its aim to become a leading global drug discovery company. Kiadis intends to use its High Resolution Screening (HRS) technology platform to deliver a pipeline of patented drug candidate molecules suitable for full pharmaceutical development.

This HRS technology has the potential to provide solutions to some of the most challenging problems in drug discovery and development, according to Kiadis – specifically screening libraries made up of complex mixtures, such as natural extracts, and de-orphanising targets generated by genomics and proteomics programmes.

As well as generating patentable lead candidates for its own drug discovery pipeline, Kiadis aims to access libraries and targets from academic or biotechnology partners.

You may also like